A comparison of New York’s traditional communicable disease surveillance system for diarrhea-associated hemolytic uremic syndrome with hospital discharge data showed a sensitivity of 65%. Escherichia coli O157:H7 was found in 63% of samples cultured from hemolytic uremic syndrome patients, and samples were more likely to be positive when collected early in illness.
Diarrhea-associated hemolytic uremic syndrome (HUS) is a major cause of acute renal failure in children (
The risk factors associated with the progression of
HUS is a severe disease that results in hospitalization. Our surveillance and hospital discharge data were used to evaluate the HUS surveillance system, estimate the number of diarrhea-associated HUS cases, and study the epidemiologic and clinical features of HUS in New York.
A confirmed case of HUS was defined as the acute onset of anemia with microangiopathic changes (i.e., schistocytes, burr cells, or helmet cells) on peripheral blood smear, acute renal injury (i.e., hematuria, proteinuria, or elevated creatinine level), and a low platelet count (platelets <150,000/mL) within 3 weeks of an acute diarrheal illness. A probable case of HUS was defined as the acute onset of anemia with microangiopathic changes, acute renal injury, and a low platelet count without a history of diarrhea in the preceding 3 weeks; or hemolytic anemia without confirmed microangiopathic changes, acute renal injury, and a low platelet count within 3 weeks of an acute diarrheal illness (
Hospital admission notes, laboratory reports, and discharge summaries were requested for patients who had HUS (International Classification of Diseases, 9th Revision, Clinical Modification [ICD-9-CM] code 283.11) listed as their primary or any secondary diagnosis for 1998 and 1999. All medical charts were reviewed, and patients were classified as having a confirmed, probable, or undetermined HUS case. Persons with multiple hospitalizations were counted only once. The records from case reports and medical charts were matched by last name, first name, and date of birth. The capture-recapture method was used to evaluate the completeness of HUS reporting and to estimate the “true” number of HUS cases and the 95% confidence interval (
Data from medical charts regarding demographic characteristics (age, sex, race, month of admission, hospital length of stay), clinical features at admission (vomiting, fever, bloody stool), and antimicrobial therapy were extracted for all confirmed or probable case-patients. Laboratory variables were obtained for patients within 7 days before and 3 days after the HUS diagnosis and included the lowest hematocrit, lowest platelet count, highest blood urea nitrogen (BUN), and highest creatinine concentrations. The Fisher exact test was used to determine the proportion of demographic and clinical characteristics among HUS patients with or without stool isolates for
Forty-five HUS case-patients reported to the New York communicable disease surveillance system for 1998 through 1999 were listed as being hospitalized; the medical charts of 44 of these patients were available for review. We requested 542 medical records that had a primary or secondary discharge diagnosis listed as HUS during the same period; 421 (78%) charts were received. After chart review, 234 records were from New York State residents, excluding New York City, and 201 patients remained for analysis after excluding duplicate records. Forty-nine patients had confirmed HUS, 10 patients had probable HUS, and 142 patients either had incomplete information to determine HUS status or did not have HUS. Among these 142 patients, 9 patients had no laboratory reports, 23 patients had renal failure and anemia with microangiopathic changes but no diarrhea; and 110 patients had no renal failure or no microangiopathic changes. Stool samples from 12 of these 142 patients were cultured for
HUS surveillance data were matched against hospital discharge data by last name, first name, and date of birth. Thirty-three confirmed and 5 probable cases were in both systems, 4 confirmed and 3 probable cases were only in the surveillance system, and 16 confirmed and 5 probable cases were only in the hospital system. The “true” total number of confirmed or probable HUS cases in New York was estimated to be 70 (95% confidence interval [CI] = 63 to 75), and the sensitivity of our surveillance system for reporting HUS was 65%.
The demographic, clinical features, and laboratory results of 53 confirmed and 12 probable diarrhea-associated HUS cases from either data system were studied. The average annual incidence was significantly greater among children <5 years of age (relative risk [RR] 17, 95% confidence interval [CI] 8.9 to 32) than among patients 15–64 years of age and was greater among female than male patients (RR 2.1, 95% CI 1.2 to 3.8) (
| Characteristic | No. of patients (N = 65) |
|---|---|
| Demographic features | No. (incidence/100,000) |
| Age (in years) | |
| <5 | 28 (2.0) |
| 5–14 | 11 (0.4) |
| 15–64 | 17 (0.1) |
| >65 | 9 (0.3) |
| Sex | |
| Male | 20 (0.2) |
| Female | 45 (0.4) |
| Race | |
| White | 57 (0.3) |
| Black | 3 (0.2) |
| Asian | 1 (0.2) |
| Outcome | No. (%) |
| Alive | 59 (91) |
| Dead | 6 (9) |
| Outbreak-associated | No. (%) |
| Yes | 15 (23) |
| No | 50 (77) |
Six patients (9%), ages 3 to 89 years, died while hospitalized; two of these deaths were outbreak related. All six patients had bloody diarrhea and blood transfusions, leukocyte counts >18,000, BUN levels >63, and serum creatinine levels >2.3. Samples from five of six were culture positive for
Of the 65 confirmed or probable HUS patients, 54 (83%) had their stool or urine tested for
| Characteristics | |||
|---|---|---|---|
| Positive (n = 34) | Negative (n = 20) | p value | |
| Mean age at admission (y) | 23.6 | 23.7 | 0.99 |
| Mean length of hospital stay (days) | 13.4 | 12.6 | 0.71 |
| Mean duration from diarrhea onset to specimen collection date (days) | 4.1 | 6.0 | 0.06 |
| Median duration from admission date to specimen collection date (days) | 0 | 1.0 | 0.02 |
| Mean BUN (mg/dL) | 62.1 | 82.6 | 0.05 |
| Mean creatinine (mg/dL) | 3.6 | 4.8 | 0.24 |
| Mean platelet count (/103) | 50.9 | 53.8 | 0.81 |
| Mean leukocyte count (/103) | 18.5 | 21.4 | 0.23 |
| % outbreak related | 38% | 5% | 0.01 |
| % blood in stool | 82% | 65% | 0.15 |
| % reported to surveillance | 88% | 55% | 0.01 |
| % microangiopathic change | 79% | 100% | 0.03 |
| % urinary tract infection | 3% | 20% | 0.04 |
aHUS, hemolytic uremic syndrome;
Most surveillance systems for communicable disease reporting are passive. The use of hospital discharge records is a conventional method to verify the completeness of reporting. A population-based study that used hospital data without reviewing medical charts estimated that 47% of hospital discharge data were reported to public health surveillance (
Seven of the 12 probable HUS case-patients had
This study showed that female patients had higher incidence rates for HUS; the incidence rates of
HUS associated with
Suggested citation for this article: Chang H-G H, Tserenpuntsag B, Kacica M, Smith PF, Morse DL. Hemolytic uremic syndrome incidence in New York. Emerg Infect Dis [serial on the Internet]. 2004 May [
We thank Nancy Spina for reviewing hospital medical charts.
This paper was presented at the International Conference on Emerging Infectious Diseases, held March 24–27, 2002, in Atlanta, Georgia, USA.
Dr. Chang is director of the Statistical Unit, Division of Epidemiology, New York State Department of Health. Her research interests focus on the epidemiology of infectious diseases.